Related Experiment Videos
Respiratory distress syndrome treated with human surfactant: radiographic findings
Insights
Human surfactant therapy significantly improved respiratory distress syndrome (RDS) in newborns. While shunts were common, surfactant did not increase respiratory assistance complications like bronchopulmonary dysplasia.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pediatrics
Background:
- Respiratory distress syndrome (RDS) is a significant cause of morbidity and mortality in newborns.
- Surfactant replacement therapy is a cornerstone in managing RDS.
Purpose of the Study:
- To evaluate the efficacy and safety of endotracheal human surfactant instillation in newborns with RDS.
- To compare radiographic findings and complications in treated versus untreated infants.
Main Methods:
- Chest radiographs of 18 newborns treated with human surfactant for RDS were compared to 18 untreated infants.
- Radiographic findings, including shunts and signs of respiratory distress, were analyzed.
- Incidence of complications such as pulmonary interstitial emphysema, pneumothorax, and bronchopulmonary dysplasia was assessed.
Main Results:
- Treated infants showed significant improvement in RDS severity post-surfactant administration.
- A high incidence of left-to-right shunts (patent ductus arteriosus) was observed in both treated (16/18) and untreated (17/18) infants.
- Complications of respiratory assistance, including transient pulmonary interstitial emphysema, pneumothorax, and bronchopulmonary dysplasia, occurred at similar rates in both groups. Three treated infants developed transient interstitial lung disease.
Conclusions:
- Endotracheal human surfactant is effective in improving RDS severity in newborns.
- Surfactant therapy did not increase the risk of common respiratory assistance complications.
- Further investigation into transient interstitial lung disease post-surfactant administration may be warranted.
Abstract:
Chest radiographs of 18 newborns treated with endotracheal instillation of human surfactant for respiratory distress syndrome (RDS) were compared with those of 18 similar but untreated infants. In the treated infants, severity of RDS significantly improved after surfactant administration. Most treated infants (16/18) exhibited a left-to-right shunt, presumably through a patent ductus arteriosus; similar findings were noted in untreated infants (17/18). Complications of respiratory assistance in the treated infants included transient pulmonary interstitial emphysema (n = 1), pneumothorax (n = 1), and mild (n = 4) to moderate (n = 2) bronchopulmonary dysplasia; the incidences of these complications did not exceed those in untreated infants. In three treated infants, a transient interstitial lung disease developed 3-4 days after surfactant administration.